BLLI-
(COMTEX) B: BioLok International Reports Record Sales for Preliminary Fisc
l Fourth Quarter and Full Year 2005 Results
B: BioLok International Reports Record Sales for Preliminary Fiscal Fourth Quart
r and Full Year 2005 Results
DEERFIELD BEACH, Fla., Nov 14, 2005 (BUSINESS WIRE) -- BioLok International
Inc. (OTCBB: BLLI), the manufacturer and worldwide distributor of leading-edge
dental implant technology, today announced preliminary fiscal fourth quarter and
full year 2005 results.
For the quarter ended October 31, 2005, the Company's sales were a record $2.1
million, an increase of 58% from the same period of fiscal 2004. Sales for the
twelve months ended October 31, 2005, were also a record at $7.2 million, up 46%
as compared to the prior fiscal year.
"The growth strategies we have been implementing are proving very successful,"
said Bruce L. Hollander, President of BioLok International. "Sales in our fiscal
fourth quarter and full year 2005 are impressive by several measures. First, in
the fourth quarter we achieved the highest level of revenues of any quarter in
our history. This is even more remarkable considering that our fourth quarter is
seasonally slower than the other three quarters. Second, we continue to grow
well in excess of the industry, which suggests our patented dental implant
products are gaining market share. Third, our momentum has continued unabated
despite the demand on management's time to expand our sales staff and for
research and development efforts, which should lead to future growth. Finally,
we achieved record sales levels even though we were negatively impacted by
Hurricane Wilma and other adverse weather conditions."
The Company expects to report final results for fiscal year 2005 with the
issuance of its 10-KSB by the end of the month.
BioLok International Inc. (OTCBB: BLLI) is merging cell biology and technology
to develop and market products for the dental implant and tissue regeneration
markets. The Company is the worldwide manufacturer and distributor of the BioLok
Precision Dental Implant System. BioLok offers a superior line of dental
implants that incorporate many patented features and are synonymous with
quality, fit of components, leading edge technology and design, and ease of use.
With funding from the National Institutes of Health (NIH) and the National
Science Foundation (NSF), BioLok's research and development subsidiary,
Orthogen, has developed and patented a proprietary laser microgrooving
technology which has been assigned to BioLok. Subsequently, BioLok applied the
technology for processing the surfaces of dental implants and related medical
products to enhance tissue attachment. The product is marketed by BioLok under
the trade name Laser-Lok(TM) and is the basis for significant revenue growth and
market share gains by the Company. The laser microgrooving technology has
potential applications for transcutaneous devices, orthopaedic implants,
peripheral nerve repair, bioreactors, cardiovascular and ophthalmic devices. The
Company has ongoing research programs with patents pending or issued in each of
these areas.
Additional information is available on the Company's Web site at www.biolok.com.
With the exception of the historical information contained in the release, the
matters described herein contain certain "forward-looking statements" that are
made pursuant to the Safe Harbor provisions of the Private Securities Litigation
Reform Act of 1995. The statements contained in this release, which are not
historical facts may be deemed to contain forward-looking statements, including,
but not limited to, deployment of new services, growth of the customer base, and
growth of the service area, among other items. Actual results may differ
materially from those anticipated in any forward-looking statement with regard
to magnitude, timing or other factors. Deviation may result from risk and
uncertainties, including, without limitation, the Company's dependence on third
parties, market conditions for the sale of services, technical factors affecting
networks, availability of capital and other risks and uncertainties. More
detailed information about these risk factors are set forth and may be updated
from time to time in filings by BioLok International, Inc. with the Securities
and Exchange Commission, including the Company's most recent quarterly report on
Form 10-Q and other publicly available information regarding the Company. The
Company disclaims any obligation to update information contained in any
forward-looking statement.
SOURCE: BioLok International
CONTACT: BioLok International
Bruce L. Hollander, 954-698-9998
blh@biolok.com
or
Investor Relations:
Darrow Associates, Inc.
Jordan M. Darrow, 631-367-1866
jdarrow@optonline.net
Copyright Business Wire 2005
-0-
KEYWORD: United States
North America
Florida
INDUSTRY KEYWORD: Health
Biotechnology
Dental
Medical Devices
Pharmaceutical
SUBJECT CODE: Earnings
*** end of story *** |
